Chronic pain patients are more supportive of cannabis access than doctors

8 in 10 cannabis users report combining marijuana with exercise, saying it boosts motivation and mood, eases pain

Adults with chronic pain are significantly more supportive of policies expanding cannabis access than the physicians who treat them, according to a study from Rutgers Health and other institutions.

The study surveyed over 1,600 individuals with chronic pain and 1,000 physicians in states with medical cannabis programs, including New Jersey. The researchers discovered that 71% of chronic pain patients were in favour of the federal legalization of medical cannabis, while 59% of physicians shared the same viewpoint.

“Cannabis has a unique and complex policy landscape,” noted Elizabeth Stone, a core faculty member at the Rutgers Institute for Health, Health Care Policy and Aging Research and the study’s lead author. “Depending on the state you’re in, medical cannabis may be legal, both medical and recreational use may be legal, neither may be legal, or some aspects may be decriminalized.”

Currently, 38 states and Washington, D.C. have legalized medical cannabis use, and New Jersey and 23 other states, along with D.C., have legalized it for adult recreational use. However, cannabis remains a Schedule I controlled substance under federal law. Schedule I drugs are considered to have the highest risk of abuse with no recognized medical use, according to the National Institutes of Health.

Among those polled for the study, 55% of chronic pain patients but 38% of physicians supported federal legalization of cannabis for adult recreational use. Some 64% of patients, but 51% of physicians, favoured requiring insurance coverage for cannabis treatment of chronic pain.

“Overall, individuals with chronic pain were more supportive of policies that would expand access to medical cannabis, while healthcare providers were more supportive of policies that would restrict access to medical cannabis,” said Stone, who is also an instructor in the Department of Psychiatry at Rutgers Robert Wood Johnson Medical School.

The researchers tapped two separate survey groups for the study data: One contained adults with noncancer pain lasting six months or more, and the other contained primary care providers and various specialty physicians.

Personal experience played a significant role in shaping attitudes for both groups. People who had used cannabis for chronic pain reported the highest levels of support for expanding access. Physicians who hadn’t recommended cannabis for chronic pain management reported the lowest levels of support.

The study also found broad support for increased education for doctors prescribing medical cannabis. About 70% of both patients and physicians favoured requiring medical schools to train future doctors on cannabis treatment for chronic noncancer pain.

“I think it points to the need for future guidance around cannabis use and efficacy,” Stone said. “Is it something they should be recommending? If so, are there different considerations for types of products or modes of use or concentration?”

AI for personalized pain medicine

A review paper by scientists at Indiana University Bloomington summarized recent engineering efforts in developing various sensors and devices to address challenges in personalized pain treatment.

The new review paper, published on September 13th in the journal Cyborg and Bionic Systems, critically examines the role of sensors and devices guided by artificial intelligence (AI) in personalized pain medicine and highlights their transformative impact on treatment outcomes and patient quality of life.

The experience of pain is complex and varies from person to person, impacting quality of life and putting strain on healthcare systems. Despite its widespread impact, accurately assessing and managing pain is challenging. “Personalized pain medicine aims to customize treatment strategies based on individual patient needs, with the potential to improve outcomes, reduce side effects, and increase patient satisfaction,” explained Feng Guo, a professor at Indiana University Bloomington. Recent engineering efforts have focused on developing sensors and devices to address these challenges in personalized pain treatment. These efforts include monitoring, assessing, and relieving pain, as well as taking advantage of advancements in medical AI, such as AI-based analgesia devices, wearable sensors, and healthcare systems.

The potential of intelligent sensors and devices to provide real-time, accurate pain assessment and treatment options represents a significant shift toward more dynamic and patient-specific approaches. However, adopting these technologies comes with substantial technical, ethical, and practical challenges, such as ensuring data privacy and integrating AI systems with existing medical infrastructures. Future research must refine algorithms and enhance system interoperability to foster broader adoption. AI-driven technologies are poised to transform the field of pain medicine, but it’s crucial to rigorously evaluate their impact and address ethical dimensions to ensure positive contributions to patient care without exacerbating existing disparities. Yantao Xing emphasized the importance of addressing these issues.

The potential of smart devices and sensors in personalized pain medicine is promising. However, challenges need to be addressed, such as data accuracy, device reliability, privacy, security concerns, and the cost of technology. This review emphasizes the need for multidisciplinary collaboration to fully utilize sensors and devices guided by AI in revolutionizing pain management. Integrating these technologies into clinical practice not only promises improved patient outcomes but also a more detailed understanding of pain mechanisms, leading to more effective and personalized treatment strategies.

Abdominal fat linked to chronic pain, especially in women

Reducing this fat may reduce chronic pain particularly if it’s at multiple body sites
“Reducing this fat may help reduce chronic pain, especially if it is present in multiple body sites.”

Reducing excess fat deposits in the abdomen may help reduce chronic musculoskeletal pain, especially if it’s experienced at multiple body sites, suggest the researchers. Previously published research has shown that obesity is associated with musculoskeletal pain. Still, it’s not known if excess fat tissue is linked to chronic musculoskeletal pain at multiple body sites, say the researchers. To find out, they drew on data from 32,409 participants in the UK Biobank study who completed questionnaires and underwent health assessments. Around half (51%) were women, and their average age was 55.

They underwent MRI scans of their abdomen to measure the amount of fat around the abdominal organs (visceral adipose tissue or VAT)  and the amount of fat just under the skin that can be pinched (subcutaneous adipose tissue or SAT).  When attending for their scan, participants were asked if they had experienced any pain in their neck/shoulder, back, hip, knee or ’all over the body’ for more than 3 months.  The MRI scan and pain assessments were repeated around 2 years later for 638 participants. Comprehensive analyses showed a dose-response association between the number of chronic pain sites and VAT, SAT, the ratio of the two, and weight (BMI).  The association was stronger in women, among whom the odds ratio of a higher number of chronic pain sites was twice as high for VAT and 60% greater for both SAT and the VAT: SAT ratio. In men, these odds ratios were 34% 39%, and 13% higher, respectively. 

Higher levels of fat tissue were also associated with greater odds of reporting chronic pain, and again the association was more pronounced in women.  All these associations remained even after adjusting for age, height, ethnicity, household income, educational attainment, alcohol intake, smoking status, physical activity, coexisting conditions, sleep duration, psychological problems and length of follow-up.

This is an observational study, and as such, can’t establish cause and effect, and the authors also acknowledge various limitations. These include the relatively small size of the repeat imaging sample and the absence of an assessment of severity in the pain questionnaire. They add that more follow-up visits would also have allowed more information to be gathered on patterns and fluctuations in the number of chronic pain sites. However, they conclude: “Abdominal adipose tissue was associated with chronic musculoskeletal pain, suggesting that excessive and ectopic fat depositions may be involved in the pathogenesis of multisite and widespread chronic musculoskeletal pain.  Therefore, reducing abdominal adiposity may be considered a target for chronic pain management, particularly in those with pain in multiple sites and widespread pain.” They suggest that the stronger associations seen in women may be a consequence of sex differences in fat distribution and hormones.

Brain scans shoe that mindfulness for pain is not a placebo

brian scan

Credit UC San Diego Health Sciences

Pain is a complex and multi-dimensional experience influenced by factors beyond just physical sensation, including a person’s mindset and their expectations of pain. The placebo effect, where symptoms improve in response to inactive treatment, demonstrates how expectations can significantly impact a person’s experience. Mindfulness meditation, which has been used for pain management in various cultures for centuries, was previously believed to work by triggering the placebo response. However, recent scientific findings have disproven this belief.

A recent study published in Biological Psychiatry discovered that mindfulness meditation activates specific brain mechanisms that differ from those involved in the placebo response, leading to a reduction in pain. Researchers at the University of California San Diego School of Medicine utilized advanced brain imaging methods to compare the pain-relieving effects of mindfulness meditation, a placebo cream, and a “sham” mindfulness meditation among healthy participants.

The research discovered that mindfulness meditation led to notable decreases in both the intensity and unpleasantness of pain, as well as a reduction in brain activity linked to pain and negative emotions. On the other hand, the placebo cream only affected brain activity related to the placebo effect without changing the person’s actual experience of pain.

“The mind is incredibly powerful, and we are still trying to understand how it can be used for managing pain,” said Fadel Zeidan, PhD, a professor of anesthesiology and Endowed Professor in Empathy and Compassion Research at UC San Diego Sanford Institute for Empathy and Compassion. “By separating pain from the self and letting go of judgment, mindfulness meditation can directly change how we experience pain. It does not involve any drugs, costs nothing, and can be practiced anywhere.”

The study involved 115 participants who took part in two separate clinical trials. The participants were randomly assigned to different groups to receive one of four interventions: guided mindfulness meditation, a sham mindfulness meditation involving only deep breathing, a placebo cream (petroleum jelly) that participants were told reduces pain, and, as a control, listening to an audiobook. The researchers applied a mildly painful but harmless heat stimulus to the back of the leg and scanned the participants’ brains before and after the interventions.

The researchers utilized a new method known as multivariate pattern analysis (MVPA) to examine the brain activity patterns of the participants. This method uses machine learning to understand the complex neural mechanisms linked to the sensation of pain. These mechanisms involve specific responses to heat stimuli, negative emotions, and pain reactions induced by the placebo effect. Using this approach, the researchers could ascertain whether mindfulness meditation and the placebo effect trigger similar or different brain processes.

Although both the placebo cream and sham mindfulness meditation reduced pain, the study revealed that mindfulness meditation was significantly more effective in pain reduction compared to the placebo cream, sham mindfulness meditation, and the controls.

They found that mindfulness-based pain relief reduced synchronization between brain areas involved in introspection, self-awareness, and emotional regulation. These areas of the brain make up the neural pain signal (NPS), a recognized pattern of brain activity associated with pain across different individuals and types of pain. On the other hand, the placebo cream and sham mindfulness meditation did not show a significant change in the NPS compared to the controls. Instead, these interventions engaged entirely separate brain mechanisms with little overlap.

“It has been widely believed that the placebo effect and the brain mechanisms activated by actual treatments are closely linked. However, these findings indicate that this may not be the case when it comes to pain,” explained Zeidan. “Instead, these two brain responses are entirely separate. This supports the idea of using mindfulness meditation as a direct treatment for chronic pain, rather than as a means of triggering the placebo effect.”

In modern medicine, new therapies are considered effective and reliable if they perform better than a placebo. A recent study discovered that mindfulness meditation is more effective than a placebo and does not activate the same neurobiological processes. These findings are significant for developing new treatments for chronic pain. However, further research is needed to confirm these effects in individuals with chronic pain as opposed to healthy participants.

The researchers aim to use their understanding of the specific brain mechanisms involved in mindfulness meditation to create better interventions. These interventions could be more effective and accessible and could help reduce pain in people with different health conditions.

“Millions of people live with chronic pain every day, and there may be more that these individuals can do to reduce their pain and enhance their quality of life than we previously understood,” said Zeidan. “We are excited to continue exploring the neurobiology of mindfulness and how we can utilize this ancient practice in the clinic.”